What is Kabra Drugs Ltd (524322) share price return in the past 10 years?

Kabra Drugs Ltd share price has appreciated 9.3% annually (CAGR) over the past ten years.

What is the share price of Kabra Drugs Ltd (524322)?

Company share prices are keep on changing according to the market conditions. The current trading price of Kabra Drugs Ltd (524322) on 04-Jun-2026 16:59:59 at 16:59 is 22.93.

What is the P/E ratio of Kabra Drugs?

The latest standalone P/E ratio of Kabra Drugs as of 04-Jun-2026 is 10.96.

What is the P/B ratio of Kabra Drugs Ltd (524322)?

The latest standalone P/B ratio of Kabra Drugs Ltd (524322) as of 04-Jun-2026 is 1.84.

What is the 52-week high and low of Kabra Drugs Ltd (524322)?

The 52-week high of Kabra Drugs Ltd (524322) is Rs. 35.52 and the 52-week low is Rs. 12.17.

Kabra Drugs Ltd (524322) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Kabra Drugs Ltd (524322)
Brand: Kabra Drugs

Kabra Drugs Ltd (524322)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524322 NSE: Pharmaceuticals & Drugs | Small Cap | Kabra Drugs Share Price

Kabra Drugs Ltd (524322)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524322 NSE: Pharmaceuticals & Drugs | Small Cap | Kabra Drugs Share Price

Key Metrics

Valuation Multiples

Market Cap

₹54 Cr.

Current Price

₹22.9

52-Week Low / High

₹12 / 36

TTM EPS

₹2.1

TTM Sales

₹92.7 Cr.

Book Value per Share

₹12.5

P/E Ratio

10.96

Industry PE

46.5

Price to Book (P/B)

1.84

Higher than its 5-year historical median

Price to Sales (P/S)

0.59

EV/EBITDA

7.59

Higher than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

-9.36%

Underperforms industry median

Return on Capital Employed (ROCE)

-7.78%

Underperforms industry median

Return on Assets (ROA)

-7.29%

Operating Profit Margin

Net Profit Margin

Gross Profit Margin

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Operating Profit Growth (1 Year)

Net Profit Growth (1 Year)

Asset Quality

Promoter Holding

0.00%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹6 Cr.

Equity

₹23.7 Cr.

Face Value

₹10

All Time Low / High

₹0.52 / 160.70

Kabra Drugs stock performance

Key Ratios

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Kabra Drugs Ltd a good quality company?

Kabra Drugs Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Kabra Drugs Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Kabra Drugs Ltd vs industry peers?

Kabra Drugs Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 6.81%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Kabra Drugs Ltd?

Promoters hold 0.00% of the Kabra Drugs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Kabra Drugs Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 9.8% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	5.8%	7.5%	-80.1%	-19.7%	-8.8%	-27.3%	-28%	-52.6%	-42.7%	-7.8%	-
Value Creation Index ⓘ	-0.6	-0.5	-6.7	-2.4	NA	NA	NA	NA	NA	-1.6	-
Growth Parameters ⓘ
Sales ⓘ	9.7	7.6	2	0	0	0	0	0	0	0	93
Sales YoY Gr.	-	-21.1%	-73.6%	-100%	NA	NA	NA	NA	NA	NA	-
Adj EPS ⓘ	0.1	0.3	-3.9	-0.4	-0.1	-0.4	-0.4	-0.8	-1.7	-0.5	2.1
YoY Gr.	-	400%	-1386.7%	NA	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	6	5.8	0.5	0.1	-0.1	-0.5	-0.9	-1.7	-3.3	10.4	12.5
Adj Net Profit ⓘ	0	0.1	-1.7	-0.2	-0.1	-0.2	-0.2	-0.3	-0.7	-1.1	5
Cash Flow from Ops. ⓘ	0.3	0.3	-0.1	-0.2	-0.1	-0.3	-0.1	-0.4	-0.2	-4.7	-
Debt/CF from Ops. ⓘ	4.5	5.8	-6.1	-3.8	-14.2	-3.6	-7.7	-3.9	-8.2	-0.1	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-100%	NA	NA	NA
Adj EPS ⓘ	-225.4%	NA	NA	NA
BVPSⓘ	6.3%	NA	NA	NA
Share Price	9.3%	37.7%	61.9%	97.2%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	1.1	5	-123.2	-144.2	-2869.3	152.9	61.7	60.1	-418.4	-8.4	18.3
Op. Profit Mgn % ⓘ	4.7	5.8	-51.5	0	0	0	0	0	0	0	5.7
Net Profit Mgn % ⓘ	0.3	1.7	-84.4	0	0	0	0	0	0	0	5.3
Debt to Equity ⓘ	0.5	0.7	3.6	21	-23.5	-4.3	-2.6	-1.9	-1.2	0	0
Working Cap Days ⓘ	213	229	460	0	0	0	0	0	0	0	114
Cash Conv. Cycle ⓘ	102	95	310	0	0	0	0	0	0	0	46

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	9.65	7.61	2.01	0	0	0	0	0	0	0
Operating Expenses ⓘ +	9.20	7.17	3.04	0.14	0.05	0.15	0.18	0.34	0.74	1.72
Manufacturing Costs	1.33	1.14	0.24	0	0	0	0	0	0	0
Material Costs	6.52	4.14	1.38	0	0	0	0	0	0	0
Employee Cost	0.68	0.83	1.18	0.03	0	0.05	0.09	0.23	0.40	0.69
Other Costs ⓘ	0.67	1.06	0.24	0.10	0.05	0.10	0.09	0.11	0.34	1.02
Operating Profit ⓘ	0.46	0.44	-1.03	-0.14	-0.05	-0.15	-0.18	-0.34	-0.74	-1.72
Operating Profit Margin (%)	4.7%	5.8%	-51.5%	-	-	-	-	-	-	-
Other Income ⓘ +	0.02	0.11	0.01	0.01	0.02	0	0	0.01	0	0.64
Exceptional Items ⓘ	0	0	-0.95	0	0	0	0	0	0	0
Interest ⓘ	0.18	0.17	0.25	0.01	0	0	0	0	0	0
Depreciation ⓘ	0.24	0.24	0.14	0.03	0.03	0.03	0.01	0	0	0.01
Profit Before Tax ⓘ	0.05	0.14	-2.36	-0.16	-0.06	-0.18	-0.19	-0.34	-0.74	-1.09
Tax ⓘ	0.02	0.01	0	0	0	0	0	0	0	0
Profit After Tax	0.03	0.13	-2.36	-0.16	-0.06	-0.18	-0.19	-0.34	-0.74	-1.09
PAT Margin (%)	0.3%	1.7%	-117.0%	-	-	-	-	-	-	-
Adjusted EPS (₹)	0.1	0.3	-5.4	-0.4	-0.1	-0.4	-0.4	-0.8	-1.7	-0.5
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Kabra Drugs - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	2.63	2.55	0.20	0.03	-0.03	-0.21	-0.39	-0.73	-1.47	24.65
Share Capital ⓘ	4.39	4.39	4.39	4.39	4.39	4.39	4.39	4.39	4.39	23.71
Reserves ⓘ	-1.76	-1.84	-4.19	-4.36	-4.42	-4.60	-4.78	-5.12	-5.86	0.95
Debt +	1.28	1.68	0.66	0.67	0.65	0.90	1.03	1.38	1.71	0.44
Long Term Debt	1.18	1.03	0.01	0.02	0	0	0	0	0	0
Short Term Debt	0.10	0.65	0.65	0.65	0.65	0.90	1.03	1.38	1.71	0.44
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	2.79	1.28	0.21	0.19	0.19	0.19	0	0	0	0
Others Liabilities ⓘ	2.47	0.88	0.63	0.59	0.60	0.52	0.10	0.05	4.33	0.14
Total Liabilities ⓘ	9.17	6.39	1.70	1.48	1.41	1.40	0.73	0.70	4.57	25.23
Fixed Assets
Net Fixed Assets ⓘ +	2.73	2.48	0.11	0.08	0.04	0.01	0	0	0	0.04
Gross Block	9.02	2.73	0.17	0.17	0.17	0.17	0.17	0.17	0	0.05
Accumulated Depreciation	6.29	0.24	0.06	0.09	0.13	0.16	0.17	0.17	0	0.01
CWIP ⓘ	0.21	0.21	0	0	0	0	0	0	0	0
Investments ⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	0.32	0.22	0	0	0	0	0	0	0	0
Trade Receivables	5.36	2.95	1.26	1.25	1.25	1.25	0.60	0.60	0.60	0.60
Cash Equivalents ⓘ	0.16	0.09	0.13	0.01	0.01	0.01	0	0	2.67	21.30
Others Assets ⓘ	0.39	0.43	0.20	0.14	0.11	0.13	0.13	0.10	1.30	3.29
Total Assets ⓘ	9.17	6.39	1.70	1.48	1.41	1.40	0.73	0.70	4.57	25.23

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	0.28	0.31	-0.12	-0.18	-0.05	-0.25	-0.13	-0.35	-0.21	-4.71
PBT ⓘ	0.05	0.14	-2.36	-0.16	-0.06	-0.18	-0.19	-0.34	-0.74	-1.09
Adjustment ⓘ	0.41	0.30	1.32	0.03	0.01	0.03	0.01	0	0	0.01
Changes in Working Capital ⓘ	-0.15	-0.12	0.94	-0.04	0	-0.1	0.04	-0.02	0.53	-3.63
Tax Paid ⓘ	-0.02	-0.01	-0.02	-0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ +	-0.29	0.01	1.50	0.07	0.06	0	0	0	0	-0.05
Capex	-0.31	-0	1.50	0	0.01	0	0	0	0	-0.05
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0.02	0.01	0	0.07	0.06	0	0	0	0	0
Cash Flow From Financing Activity ⓘ +	-0.27	-0.32	-1.35	-0	-0.02	0.25	0.13	0.36	2.88	23.39
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	2.55	24.66
Net Proceeds from Borrowing ⓘ	0	0	-1.10	0.01	-0.02	0	0	0	0	0
Interest Paid ⓘ	-0.18	-0.17	-0.25	-0.01	-0	0	0	0	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-0.09	-0.15	0	0	0	0.25	0.13	0.36	0.33	-1.27
Net Cash Flow ⓘ	-0.28	-0	0.04	-0.10	0	-0	-0.01	0	2.67	18.63

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	1.05	5.02	-171.4	-144.2	N/A	N/A	N/A	N/A	N/A	-9.36
ROCE (%)	5.81	7.49	-80.09	-19.67	N/A	N/A	N/A	N/A	N/A	-7.78
Asset Turnover Ratio	1.09	0.99	0.5	0	0	0	0	0	0	0
PAT to CFO Conversion(x)	9.33	2.38	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	185.90	197.10	383.20	0	0	0	0	0	0	0
Inventory Days	13.80	12.80	0	0	0	0	0	0	0	0
Payable Days	136.20	179.20	196.10	0	0	0	0	0	0	0

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Kabra Drugs Ltd FAQs

The current trading price of Kabra Drugs on 04-Jun-2026 16:59 is ₹22.93.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Kabra Drugs stood at ₹54.36 Cr

The latest P/E ratio of Kabra Drugs as of 03-Jun-2026 is 10.96.

The latest P/B ratio of Kabra Drugs as of 03-Jun-2026 is 1.84.

The 52-week high of Kabra Drugs is ₹35.52 and the 52-week low is ₹12.17.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kabra Drugs is ₹92.74 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Kabra Drugs Ltd is a below average quality company.

The key valuation ratios of Kabra Drugs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Kabra Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Kabra Drugs Ltd

Kabra Drugs Ltd. is a limited company incorporated under the Companies Act, 1956 on August 22, 1989 having its registered office at 270 Shastri Market Indore, MP. The company is a public limited Company and its shares are listed on Bombay stock exchange (BSE).

Business area of the company

The company is presently engaged in the business of Permaculture manufacturing and trading in pharma related products.

Kabra Drugs Ltd (524322)

Kabra Drugs Ltd (524322)

Kabra Drugs stock performance